BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Potsch DV, Camacho LA, Tuboi S, Villar LM, Miguel JC, Ginuíno C, Silva EF, Mendonça RM, Moreira RB, Barroso PF. Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults. Vaccine. 2012;30:5973-5977. [PMID: 22828589 DOI: 10.1016/j.vaccine.2012.07.028] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Fuster F, Vargas JI, Jensen D, Sarmiento V, Acuña P, Peirano F, Fuster F, Arab JP, Martínez F; Core-HIV Study Group. CD4/CD8 ratio as a predictor of the response to HBV vaccination in HIV-positive patients: A prospective cohort study. Vaccine 2016;34:1889-95. [PMID: 26945101 DOI: 10.1016/j.vaccine.2016.02.055] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
2 Morsica G, Bagaglio S, Spagnuolo V, Castagna A, Di Serio C, Galli A, Della Torre L, Andolina A, Pramov A, Uberti-Foppa C. Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study. PLoS One 2017;12:e0184128. [PMID: 28863182 DOI: 10.1371/journal.pone.0184128] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
3 Allard N, Cowie B. Hepatitis B in men who have sex with men and HIV-infected individuals: missed opportunities and future challenges. Sex Health 2014;11:1. [DOI: 10.1071/sh13166] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Barrière J, Re D, Peyrade F, Carles M. Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer. Eur J Cancer 2021;154:66-72. [PMID: 34243079 DOI: 10.1016/j.ejca.2021.06.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 Rech-Medeiros AF, Marcon PDS, Tovo CDV, de Mattos AA. Evaluation of response to hepatitis B virus vaccine in adults with human immunodeficiency virus. Ann Hepatol 2019;18:725-9. [PMID: 31176604 DOI: 10.1016/j.aohep.2019.03.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Sun HY, Sheng WH, Tsai MS, Lee KY, Chang SY, Hung CC. Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: A review. World J Gastroenterol 2014; 20(40): 14598-14614 [PMID: 25356024 DOI: 10.3748/wjg.v20.i40.14598] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
7 Corti C, Antonarelli G, Scotté F, Spano JP, Barrière J, Michot JM, André F, Curigliano G. Seroconversion rate after vaccination against COVID-19 in cancer patients-a systematic review. Ann Oncol 2021:S0923-7534(21)04550-6. [PMID: 34718117 DOI: 10.1016/j.annonc.2021.10.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Whitaker JA, Rouphael NG, Edupuganti S, Lai L, Mulligan MJ. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis. 2012;12:966-976. [PMID: 23174382 DOI: 10.1016/s1473-3099(12)70243-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 23] [Article Influence: 4.9] [Reference Citation Analysis]
9 Filippelli M, Lionetti E, Gennaro A, Lanzafame A, Arrigo T, Salpietro C, La Rosa M, Leonardi S. Hepatitis B vaccine by intradermal route in non responder patients: An update. World J Gastroenterol 2014; 20(30): 10383-10394 [PMID: 25132754 DOI: 10.3748/wjg.v20.i30.10383] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
10 Atkinson A, Miro JM, Mocroft A, Reiss P, Kirk O, Morlat P, Ghosn J, Stephan C, Mussini C, Antoniadou A, Doerholt K, Girardi E, De Wit S, Kraus D, Zwahlen M, Furrer H; Opportunistic Infections Working Group of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL. J Int AIDS Soc 2021;24:e25726. [PMID: 34118121 DOI: 10.1002/jia2.25726] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Neukam K, Gutiérrez-Valencia A, Llaves-Flores S, Espinosa N, Viciana P, López-Cortés LF. Response to a reinforced hepatitis B vaccination scheme in HIV-infected patients under real-life conditions. Vaccine 2019;37:2758-63. [PMID: 30981625 DOI: 10.1016/j.vaccine.2019.03.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lithgow D, Cole C. A reinvestigation of seroconversion rates in hepatits B-vaccinated individuals. Biol Res Nurs 2015;17:49-54. [PMID: 25504950 DOI: 10.1177/1099800414524619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Hastie E, Wooten D. Hepatitis B Virus Screening and Vaccination in Patients With HIV: A Survey of Clinicians' Current Practices. Open Forum Infect Dis 2021;8:ofab270. [PMID: 34631922 DOI: 10.1093/ofid/ofab270] [Reference Citation Analysis]
14 Kaltsas A, Sepkowitz K. Vaccinations for healthcare personnel: update on influenza, hepatitis B, and pertussis. Curr Opin Infect Dis 2013;26:366-77. [PMID: 23806899 DOI: 10.1097/QCO.0b013e3283630ee5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
15 Herrero-Fernández I, Pacheco YM, Genebat M, Rodriguez-Méndez MDM, Lozano MDC, Polaino MJ, Rosado-Sánchez I, Tarancón-Diez L, Muñoz-Fernández MÁ, Ruiz-Mateos E, Leal M. Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response. Antimicrob Agents Chemother 2018;62:e02050-17. [PMID: 29084751 DOI: 10.1128/AAC.02050-17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
16 Feng Y, Yao T, Chang Y, Gao L, Shao Z, Dong S, Wu Y, Shi X, Shi J, Feng D, Cheng Y, Pan M, Li C, Wang J, Lan G, Lu H, Wang P, Xiang S, Nong L, Wang F, Liang X, Wang S. Immunogenicity and persistence of high-dose recombinant hepatitis B vaccine in adults infected with human immunodeficiency virus in China: A randomized, double-blind, parallel controlled trial. Vaccine 2021;39:3582-9. [PMID: 34052065 DOI: 10.1016/j.vaccine.2021.05.044] [Reference Citation Analysis]
17 Andersen KL, Larsen CS, Petersen MS, Leutscher PD. Need for improvements in the surveillance and management of chronic viral hepatitis in HIV patients followed in a Danish outpatient clinic. Scand J Infect Dis 2014;46:578-84. [PMID: 24934989 DOI: 10.3109/00365548.2014.918648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Wang ZZ, Gao YH, Wang P, Wei L, Xie CP, Yang ZX, Lan J, Fang ZL, Zeng Y, Yan L, Liu XE, Zhuang H. Comparison of immunogenicity between hepatitis B vaccines with different dosages and schedules among healthy young adults in China: A 2-year follow-up study. Hum Vaccin Immunother 2018;14:1475-82. [PMID: 29420134 DOI: 10.1080/21645515.2018.1438090] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Flores GL, Cruz HM, Miguel JC, Potsch DV, Pilotto JH, Lewis-Ximenez LL, Lampe E, Villar LM. Assessing hepatitis B immunity using dried blood spot samples from HIV+ individuals. J Med Virol 2018;90:1863-7. [PMID: 30085359 DOI: 10.1002/jmv.25275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Belle A, Baumann C, Bigard MA, Zallot C, Gizard E, Guéant JL, Bronowicki JP, Peyrin-Biroulet L. Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2015;27:877-81. [PMID: 26121376 DOI: 10.1097/MEG.0000000000000370] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
21 Mena G, García-Basteiro AL, Bayas JM. Hepatitis B and A vaccination in HIV-infected adults: A review. Hum Vaccin Immunother 2015;11:2582-98. [PMID: 26208678 DOI: 10.1080/21645515.2015.1055424] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 6.1] [Reference Citation Analysis]
22 Chang L, Lim BCW, Flaherty GT, Torresi J. Travel vaccination recommendations and infection risk in HIV-positive travellers. J Travel Med 2019;26:taz034. [PMID: 31066446 DOI: 10.1093/jtm/taz034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
23 Thacher EG, Cavassini M, Audran R, Thierry AC, Bollaerts A, Cohen J, Demoitié MA, Ejigu D, Mettens P, Moris P, Ofori-Anyinam O, Spertini F. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial. AIDS 2014;28:1769-81. [PMID: 24911353 DOI: 10.1097/QAD.0000000000000343] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
24 Martins Rde M, Possas Cde A, Homma A. Historical review of clinical vaccine studies at Oswaldo Cruz Institute and Oswaldo Cruz Foundation--technological development issues. Mem Inst Oswaldo Cruz 2015;110:114-24. [PMID: 25742271 DOI: 10.1590/0074-02760140346] [Reference Citation Analysis]
25 Farooq PD, Sherman KE. Hepatitis B Vaccination and Waning Hepatitis B Immunity in Persons Living with HIV. Curr HIV/AIDS Rep 2019;16:395-403. [PMID: 31468298 DOI: 10.1007/s11904-019-00461-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
26 Martins S, Livramento Ad, Andrigueti M, Kretzer IF, Machado MJ, Spada C, Treitinger A. Vaccination coverage and immunity against hepatitis B among HIV-infected patients in South Brazil. Braz J Infect Dis 2015;19:181-6. [PMID: 25626960 DOI: 10.1016/j.bjid.2014.12.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
27 Chaiwarith R, Praparattanapan J, Kotarathititum W, Wipasa J, Chaiklang K, Supparatpinyo K. Higher rate of long-term serologic response of four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: 4-year follow-up of a randomised controlled trial. AIDS Res Ther 2019;16:33. [PMID: 31711528 DOI: 10.1186/s12981-019-0249-8] [Reference Citation Analysis]
28 Laksananun N, Praparattanapan J, Kotarathititum W, Supparatpinyo K, Chaiwarith R. Immunogenicity and safety of 4 vs. 3 standard doses of HBV vaccination in HIV-infected adults with isolated anti-HBc antibody. AIDS Res Ther 2019;16:10. [PMID: 31053142 DOI: 10.1186/s12981-019-0225-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
29 Catherine FX, Piroth L. Hepatitis B virus vaccination in HIV-infected people: A review. Hum Vaccin Immunother 2017;13:1-10. [PMID: 28267387 DOI: 10.1080/21645515.2016.1277844] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
30 Rey D, Piroth L, Wendling MJ, Miailhes P, Michel ML, Dufour C, Haour G, Sogni P, Rohel A, Ajana F, Billaud E, Molina JM, Launay O, Carrat F; ANRS HB04 B-BOOST study group. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infect Dis 2015;15:1283-91. [PMID: 26257021 DOI: 10.1016/S1473-3099(15)00220-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
31 Okulicz JF, Mesner O, Ganesan A, O'Bryan TA, Deiss RG, Agan BK. Hepatitis B vaccine responsiveness and clinical outcomes in HIV controllers. PLoS One 2014;9:e105591. [PMID: 25144773 DOI: 10.1371/journal.pone.0105591] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
32 Shah DP, Grimes CZ, Nguyen AT, Lai D, Hwang LY. Long-term effectiveness of accelerated hepatitis B vaccination schedule in drug users. Am J Public Health 2015;105:e36-43. [PMID: 25880946 DOI: 10.2105/AJPH.2014.302487] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
33 Chaiklang K, Wipasa J, Chaiwarith R, Praparattanapan J, Supparatpinyo K. Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: a randomized, controlled trial. PLoS One 2013;8:e80409. [PMID: 24265819 DOI: 10.1371/journal.pone.0080409] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
34 Schnittman SR, Zepf R, Cocohoba J, Sears D. Brief Report: Heplisav-B Seroprotection in People With HIV: A Single-Center Experience. J Acquir Immune Defic Syndr 2021;86:445-9. [PMID: 33196553 DOI: 10.1097/QAI.0000000000002573] [Reference Citation Analysis]
35 Kourkounti S, Retsas T, Paparizos V, Tsimpidakis A, Kapsimali V, Rigopoulos D. Evaluation of a convenient vaccination schedule against hepatitis B in HIV-patients with undetectable HIV viral load. Vaccine 2018;36:1533-6. [PMID: 29449101 DOI: 10.1016/j.vaccine.2018.02.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]